PHAR Stock Overview
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PHAR from our risk checks.
Pharming Group N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €7.76 |
| 52 Week High | €13.20 |
| 52 Week Low | €6.65 |
| Beta | 0.81 |
| 11 Month Change | -13.17% |
| 3 Month Change | 2.65% |
| 1 Year Change | -33.39% |
| 33 Year Change | -9.45% |
| 5 Year Change | n/a |
| Change since IPO | -53.53% |
Recent News & Updates
Shareholder Returns
| PHAR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.8% | -3.7% | 0.3% |
| 1Y | -33.4% | 15.2% | 31.1% |
Return vs Industry: PHAR underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: PHAR underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| PHAR volatility | |
|---|---|
| PHAR Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PHAR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PHAR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 382 | Simon de Vries | www.pharming.com |
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Pharming Group N.V. Fundamentals Summary
| PHAR fundamental statistics | |
|---|---|
| Market cap | US$494.19m |
| Earnings (TTM) | -US$17.82m |
| Revenue (TTM) | US$285.75m |
1.7x
P/S Ratio-27.7x
P/E RatioIs PHAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAR income statement (TTM) | |
|---|---|
| Revenue | US$285.75m |
| Cost of Revenue | US$30.30m |
| Gross Profit | US$255.44m |
| Other Expenses | US$273.26m |
| Earnings | -US$17.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.026 |
| Gross Margin | 89.39% |
| Net Profit Margin | -6.24% |
| Debt/Equity Ratio | 42.3% |
How did PHAR perform over the long term?
See historical performance and comparison